Casein Kinase II Inhibitor IV Hydrochloride is a small-molecule inducer of epidermal keratinocyte differentiation, offering novel therapeutic approaches for treating skin hyperproliferative disorders.

Treatment with Casein Kinase II Inhibitor IV enhances early differentiation in human epidermal keratinocytes (NHEKs), evidenced by increased keratins 1 and 10 expression at 48 hours. Levels of IVL and TGM also rise at 72 hours and remain elevated at 96 hours. Furthermore, this treatment induces expression of loricrin, a marker of terminal differentiation, at later stages. mRNA expression analysis corroborates these findings, showing early upregulation of keratinocyte differentiation marker genes keratin 1 (5.4-fold) and keratin 10 (5.4-fold) at 12 and 24 hours, while genes marking terminal differentiation, including IVL (1.8-fold), TGM 1 (4.8-fold), loricrin (3.3-fold), and filaggrin (5.6-fold), are significantly increased at 36 and 48 hours. These consistent results underscore Casein Kinase II Inhibitor IV's capacity to drive the differentiation of epidermal progenitor cells into terminally differentiated keratinocytes [1].